NASDAQ:INMD - InMode Stock Price, Forecast & News

InMode's stock was trading at $24.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INMD shares have decreased by 9.7% and is now trading at $22.04. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMode.

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, May 19th 2020. View our earnings forecast for InMode.

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings data on Tuesday, February, 18th. The healthcare company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.39 by $0.07. The healthcare company had revenue of $47 million for the quarter, compared to analysts' expectations of $42.48 million. InMode had a net margin of 39.10% and a return on equity of 52.38%. The firm's revenue for the quarter was up 63.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.22 earnings per share. View InMode's earnings history.

InMode updated its FY 2020 Pre-Market earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of 1.85-1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.70. The company issued revenue guidance of $190-198 million, compared to the consensus revenue estimate of $190.58 million.

4 brokers have issued 1 year price targets for InMode's shares. Their forecasts range from $28.00 to $55.00. On average, they expect InMode's stock price to reach $42.25 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts' price targets for InMode.

News stories about INMD stock have trended extremely negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. InMode earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutInMode.

InMode saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,810,000 shares, an increase of 19.8% from the February 13th total of 3,180,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the short-interest ratio is presently 2.2 days. Currently, 27.8% of the shares of the stock are short sold. View InMode's Current Options Chain.

Some companies that are related to InMode include LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), AxoGen (AXGN), Viewray (VRAY), Zynex (ZYXI), TransMedics Group (TMDX), Semler Scientific (SMLR), BioLife Solutions (BLFS), Stereotaxis (STXS), Cutera (CUTR), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO) and Fonar (FONR).

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Trade Desk (TTD), salesforce.com (CRM), Zscaler (ZS), AbbVie (ABBV), Walt Disney (DIS), Crowdstrike (CRWD) and Netflix (NFLX).

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

InMode's lock-up period expired on Tuesday, February 4th. InMode had issued 5,000,000 shares in its public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

InMode's stock is owned by a number of retail and institutional investors. Top institutional investors include Penserra Capital Management LLC (0.87%), UBS Group AG (0.34%), Norges Bank (0.17%), Fred Alger Management LLC (0.13%), Alliancebernstein L.P. (0.12%) and Ativo Capital Management LLC (0.11%).

INMD stock was sold by a variety of institutional investors in the last quarter, including Penserra Capital Management LLC, Alliancebernstein L.P., Jane Street Group LLC, Emerald Advisers LLC, Raymond James & Associates, Steward Partners Investment Advisory LLC, and Optimum Investment Advisors.

INMD stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Norges Bank, Cetera Advisors LLC, Oxford Asset Management LLP, Telemus Capital LLC, Acadian Asset Management LLC, Ativo Capital Management LLC, and Standard Life Aberdeen plc.

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INMD stock can currently be purchased for approximately $22.04.

InMode has a market capitalization of $704.62 million and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe. View additional information about InMode.

The official website for InMode is http://www.inmodemd.com/.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]